OncoMatch/Clinical Trials/NCT05918328
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Is NCT05918328 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Albumin paclitaxel+trastuzumab+pyrrolitinib and Docetaxel+Carboplatin+trastuzumab+Parstuzumab for breast cancer.
Treatment: Albumin paclitaxel+trastuzumab+pyrrolitinib · Docetaxel+Carboplatin+trastuzumab+Parstuzumab — At present, the incidence rate of breast cancer has exceeded that of lung cancer, becoming the largest cancer in the world. HER2 overexpression breast cancer accounts for about 20%\~30% of all breast cancer patients. HER2 is an important prognostic indicator and therapeutic target for breast cancer. Targeted therapy for HER2 protein is the core treatment of this type of breast cancer. Previous studies have confirmed that TKI drugs can reverse the resistance of large molecule monoclonal antibodies to a certain extent; Moreover, due to the complementarity of therapeutic targets, monoclonal antibodies are associated with TKI Drugs have synergistic effects. TCbHP is one of the preferred neoadjuvant chemotherapy schemes recommended by NCCN guidelines for HER2 positive breast cancer, but its incidence of adverse reactions such as vomiting, diarrhea, anemia, thrombocytopenia is significantly higher than that of the scheme without platinum. In the GeparOcto study and Geparsixto study, based on anthracycline+purple shirt+double target, the addition of carboplatin did not further improve the PCR rate of HER2 positive breast cancer neoadjuvant therapy. GeparSepto research showed that compared to the solvent based paclitaxel group, albumin paclitaxel increased the pCR rate by 8.2% and the IDFS by 7.3%. In the CA024 study, compared to docetaxel, albumin paclitaxel also significantly increased ORR and PFS. In the study by Lavasani SM et al., the neoadjuvant therapy of albumin paclitaxel combined with topiramate achieved a PCR rate of 64%. Therefore, we assume that the new adjuvant treatment scheme of Nab PH+pyrrolitinib can not be inferior to the efficacy of TCbHP, and has a lower incidence of adverse reactions, which may become a new adjuvant treatment option for HER2 positive breast cancer patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (ihc 3+ or fish positive)
Disease stage
Required: Stage T4D, T1C WITH AXILLARY LN+
Excluded: Stage IV
Clinical T2-T4d, or T1c with axillary LN+. Stage IV (metastatic) breast cancer [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Has received chemotherapy, endocrine therapy, targeted therapy, reflex therapy, etc. for this disease
Cannot have received: endocrine therapy
Has received chemotherapy, endocrine therapy, targeted therapy, reflex therapy, etc. for this disease
Cannot have received: targeted therapy
Has received chemotherapy, endocrine therapy, targeted therapy, reflex therapy, etc. for this disease
Cannot have received: reflex therapy
Has received chemotherapy, endocrine therapy, targeted therapy, reflex therapy, etc. for this disease
Lab requirements
Blood counts
Absolute value of neutrophil count ≥ 2.0 × 10^9/L; Hemoglobin ≥ 90g/L; Platelet count ≥ 100 × 10^9/L
Kidney function
Creatinine <1.5 × ULN
Liver function
Total bilirubin <1.5 ULN; AST/ALT < 1.5 × ULN
Cardiac function
Left ventricular ejection fraction (LVEF ≥ 55%)
Organ and bone marrow function tests within one month before chemotherapy indicate no contraindications to chemotherapy: Absolute value of neutrophil count ≥ 2.0 × 10^9/L; Hemoglobin ≥ 90g/L; Platelet count ≥ 100 × 10^9/L; Total bilirubin <1.5 ULN; Creatinine <1.5 × ULN; AST/ALT < 1.5 × ULN. Cardiac ultrasound: Left ventricular ejection fraction (LVEF ≥ 55%).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify